Most of the research behind BPC-157 comes from preclinical studies focused on tissue repair, gut integrity, and inflammation, not on body fat reduction, appetite suppression, or metabolic rate
In pre-clinical models, BPC 157 has been observed to: Upregulate vascular endothelial growth factor (VEGF) , promoting new blood vessel formation in damaged tissue Modulate nitric oxide (NO) synthesis pathways, influencing vascular tone and healing cascades Interact with the growth hormone receptor system , potentially amplifying downstream tissue repair signaling Demonstrate cytoprotective effects along the gastrointestinal tract its native home territory as a gastric peptide Exhibit apparent neuroprotective properties in rodent models of CNS injury BPC 157 stability in gastric acid unusual for peptides has made it a focus of GI mucosal repair research
J.ThomsonJ
Achieve sustainable weight loss
Wesdyk defended the process, saying scientists reviewed everything that came in by the deadline
Both are referenced here for laboratory research purposes only and are not approved for human consumption or medical use.